CClinicalTrials.gg
Not yet recruitingNCT07501962Updated Mar 30, 2026

Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate

An interventional study of Endoscopic irrigation was performed using a 0.1% menthol solution combined with simethicone. and Endoscopic irrigation was performed using an aqueous suspension prepared with simethicone and normal saline. in Colonoscopy, sponsored by The First Affiliated Hospital of Zhengzhou University. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by The First Affiliated Hospital of Zhengzhou University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In recent years, with increasing research into antispasmodic agents, topical antispasmodics have attracted considerable attention due to their direct action on the gastrointestinal mucosa and relatively low incidence of adverse reactions. Menthol, a natural terpenoid compound found in peppermint oil, has been confirmed by numerous studies to possess spasmolytic properties. Existing evidence indicates that menthol relaxes intestinal smooth muscle and alleviates spasm symptoms by antagonizing L-type calcium channels on the smooth muscle cell membrane, thereby reducing calcium influx. Furthermore, it exhibits local analgesic effects and can attenuate visceral hypersensitivity. Some studies suggest that oral or topical administration of peppermint oil preparations may improve intestinal spasm during colonoscopy, highlighting its potential utility in digestive endoscopy procedures. Nevertheless, current research on the spasmolytic efficacy and safety of menthol solution when administered via endoscopic irrigation during colonoscopy remains limited, and high-quality clinical trials are urgently needed for validation. This study aims to investigate the effectiveness and safety of menthol solution in relieving intestinal spasm, thereby providing scientific evidence for optimizing colonoscopy procedures.

02

Conditions studied

  • Colonoscopy
03

In context

Lead sponsor

The First Affiliated Hospital of Zhengzhou University is the lead sponsor of 123 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age between 18 and 75 years, regardless of gender;
  2. Scheduled to undergo colonoscopy (for screening, diagnostic, or follow-up purposes);
  3. Adequate bowel preparation quality (Boston Bowel Preparation Scale score ≥ 6);
  4. Voluntarily signed informed consent and able to cooperate with completing study-related assessments.

Exclusion criteria

Exclusion Criteria:

  1. Allergy to menthol, cyclodextrin, or related substances;
  2. History of severe intestinal diseases (such as ulcerative colitis, Crohn's disease, intestinal perforation, intestinal obstruction, intestinal tumors, etc.);
  3. Presence of severe dysfunction of vital organs such as the heart, liver, kidneys, or lungs, or coagulation disorders;
  4. Pregnant or lactating women;
  5. Use of anticholinergic drugs, calcium channel blockers, or other spasmolytic agents within one week prior to the examination;
  6. Psychiatric disorders or cognitive impairment that prevent cooperation with the study;
  7. History of contraindications to colonoscopy or serious adverse reactions during previous procedures.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    Menthol group

    Endoscopic irrigation was performed using a 0.1% menthol solution combined with simethicone. Preparation method: Normal saline was used as the solvent. Menthol cyclodextrin inclusion complex (containing 7.3% menthol) was accurately weighed at 6.85 g and dissolved in 500 ml of normal saline to prepare a 0.1% menthol solution. After complete dissolution, 5 g of simethicone was added to form an aqueous suspension.

    Drug: Endoscopic irrigation was performed using a 0.1% menthol solution combined with simethicone.

  • Placebo comparator
    placebo group

    Endoscopic irrigation was performed using an aqueous suspension prepared with simethicone and normal saline. Preparation method: 5 g of simethicone was added to 500 ml of normal saline to form the aqueous suspension.

    Drug: Endoscopic irrigation was performed using an aqueous suspension prepared with simethicone and normal saline.

Interventions

  • DrugEndoscopic irrigation was performed using a 0.1% menthol solution combined with simethicone.

    Preparation method: Normal saline was used as the solvent. Menthol cyclodextrin inclusion complex (containing 7.3% menthol) was accurately weighed at 6.85 g and dissolved in 500 ml of normal saline to prepare a 0.1% menthol solution. After complete dissolution, 5 g of simethicone was added to form an aqueous suspension.

  • DrugEndoscopic irrigation was performed using an aqueous suspension prepared with simethicone and normal saline.

    Preparation method: 5 g of simethicone was added to 500 ml of normal saline to form the aqueous suspension.

06

What researchers measure

Primary outcomes

  1. Incidence of intestinal spasm

    Intestinal spasm score: Score 1 (Excellent): No spasm; the lumen opening is greater than or equal to two-thirds of the maximum diameter. Score 2 (Moderate): Moderate spasm; the lumen opening is less than two-thirds of the maximum diameter. Score 3 (Poor): Severe spasm; the oral-side lumen cannot be visualized. The maximum diameter is defined as the diameter of the intestinal lumen when fully distended. Spasm incidence: The percentage of patients with an intestinal spasm score of 2 or 3 out of the total number of patients in the group.

    Time frame: Day 0

  2. adenoma detection rate (ADR)

    ADR = (Number of patients with at least one adenomatous polyp detected / Total number of patients in the group) × 100%. Pathological diagnosis was used as the gold standard.

    Time frame: Day 0

Secondary outcomes

  1. Spasm inhibition rate

    The percentage of patients whose lumen opening exceeded two-thirds of the maximum diameter within 30 seconds after water injection irrigation, relative to the total number of patients in the group.

    Time frame: Day 0

  2. Polyp detection rate (PDR)

    PDR = (Number of patients with at least one polyp detected / Total number of patients in the group) × 100%.

    Time frame: Day 0

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07501962
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Responsible party
Jianning Yao (Chief Physician, The First Affiliated Hospital of Zhengzhou University) — Principal investigator
First posted
Mar 30, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 30, 2026

Study contacts

Jianning Yao
Contact
rjyy@zzu.edu.cn
13733183434

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion